
## Nathalie Wauthoz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8351839/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Inhaled cytotoxic chemotherapy: clinical challenges, recent developments, and future prospects. Expert Opinion on Drug Delivery, 2021, 18, 333-354.	5.0	17
2	The combination of an innovative dry powder for inhalation and a standard cisplatin-based chemotherapy in view of therapeutic intensification against lung tumours. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 164, 93-104.	4.3	6
3	Development of Neutralizing Multimeric Nanobody Constructs Directed against IL-13: From Immunization to Lead Optimization. Journal of Immunology, 2021, 207, 2608-2620.	0.8	5
4	The Position of Inhaled Chemotherapy in the Care of Patients with Lung Tumors: Clinical Feasibility and Indications According to Recent Pharmaceutical Progresses. Cancers, 2019, 11, 329.	3.7	37
5	Tumor Targeting by Peptide-Decorated Gold Nanoparticles. Molecular Pharmaceutics, 2019, 16, 2430-2444.	4.6	37
6	How to characterize a nasal product. The state of the art of in vitro and ex vivo specific methods. International Journal of Pharmaceutics, 2019, 561, 47-65.	5.2	55
7	Nanomedicine-Based Inhalation Treatments for Lung Cancer. , 2019, , 249-268.		9
8	New Folate-Grafted Chitosan Derivative To Improve Delivery of Paclitaxel-Loaded Solid Lipid Nanoparticles for Lung Tumor Therapy by Inhalation. Molecular Pharmaceutics, 2018, 15, 899-910.	4.6	112
9	Impact of capsule type on aerodynamic performance of inhalation products: A case study using a formoterol-lactose binary or ternary blend. International Journal of Pharmaceutics, 2018, 553, 47-56.	5.2	12
10	Chitosan-coated liposome dry-powder formulations loaded with ghrelin for nose-to-brain delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 129, 257-266.	4.3	50
11	Optimization and scaling-up of ITZ-based dry powders for inhalation. Journal of Drug Delivery Science and Technology, 2017, 37, 147-157.	3.0	7
12	Stealth nanocarriers based sterosomes using PEG post-insertion process. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 115, 31-38.	4.3	11
13	Sensitization of glioblastoma tumor micro-environment to chemo- and immunotherapy by Galectin-1 intranasal knock-down strategy. Scientific Reports, 2017, 7, 1217.	3.3	105
14	Platinum pharmacokinetics in mice following inhalation of cisplatin dry powders with different release and lung retention properties. International Journal of Pharmaceutics, 2017, 517, 359-372.	5.2	19
15	Proposed algorithm for healthcare professionals based on product characteristics and in vitro performances in different use conditions using formoterol-based marketed products for inhalation. International Journal of Pharmaceutics, 2017, 530, 415-429.	5.2	5
16	Development of coated liposomes loaded with ghrelin for nose-to-brain delivery for the treatment of cachexia. International Journal of Nanomedicine, 2017, Volume 12, 8531-8543.	6.7	40
17	Development of controlled-release cisplatin dry powders for inhalation against lung cancers. International Journal of Pharmaceutics, 2016, 515, 209-220.	5.2	46
18	Rosuvastatin and vascular oxidative stress induced by diesel exhaust particles. Acta Cardiologica, 2016, 71, 565-572.	0.9	1

## NATHALIE WAUTHOZ

#	Article	IF	CITATIONS
19	Development and evaluation of well-tolerated and tumor-penetrating polymeric micelle-based dry powders for inhaled anti-cancer chemotherapy. International Journal of Pharmaceutics, 2016, 501, 148-159.	5.2	34
20	Development of siRNA-loaded chitosan nanoparticles targeting Galectin-1 for the treatment of glioblastoma multiforme via intranasal administration. Journal of Controlled Release, 2016, 227, 71-81.	9.9	123
21	Quantitative assay of capreomycin oleate levels in a drug formulation for inhalation with a fully validated HPLC method. Journal of Pharmaceutical and Biomedical Analysis, 2016, 120, 413-418.	2.8	2
22	New dry powders for inhalation containing temozolomide-based nanomicelles for improved lung cancer therapy. International Journal of Oncology, 2015, 47, 1131-1142.	3.3	20
23	Safe lipid nanocapsule-based gel technology to target lymph nodes and combat mediastinal metastases from an orthotopic non-small-cell lung cancer model in SCID-CB17 mice. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 1237-1245.	3.3	22
24	Recent Developments in Inhaled Triazoles Against Invasive Pulmonary Aspergillosis. Current Fungal Infection Reports, 2014, 8, 331-342.	2.6	5
25	Phospholipids in pulmonary drug delivery. European Journal of Lipid Science and Technology, 2014, 116, 1114-1128.	1.5	39
26	Pharmacokinetic evaluation in mice of amorphous itraconazole-based dry powder formulations for inhalation with high bioavailability and extended lung retention. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 86, 46-54.	4.3	23
27	Cyclic versus Hemi-Bastadins. Pleiotropic Anti-Cancer Effects: from Apoptosis to Anti-Angiogenic and Anti-Migratory Effects. Molecules, 2013, 18, 3543-3561.	3.8	18
28	Synthesis and plasma pharmacokinetics in CD-1 mice of a 18β-glycyrrhetinic acid derivative displaying anti-cancer activity. Journal of Pharmacy and Pharmacology, 2013, 65, 402-410.	2.4	5
29	Ophiobolin A, a sesterterpenoid fungal phytotoxin, displays higher in vitro growth-inhibitory effects in mammalian than in plant cells and displays in vivo antitumor activity. International Journal of Oncology, 2013, 43, 575-585.	3.3	33
30	Formulations for Intranasal Delivery of Pharmacological Agents to Combat Brain Disease: A New Opportunity to Tackle GBM?. Cancers, 2013, 5, 1020-1048.	3.7	126
31	New Respirable and Fast Dissolving Itraconazole Dry Powder Composition for the Treatment of Invasive Pulmonary Aspergillosis. Pharmaceutical Research, 2012, 29, 2845-2859.	3.5	22
32	In vitro and in vivo evaluation of a dry powder endotracheal insufflator device for use in dose-dependent preclinical studies in mice. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 81, 627-634.	4.3	45
33	Trivanillic polyphenols with anticancer cytostatic effects through the targeting of multiple kinases and intracellular Ca <sup>2+</sup> release. Journal of Cellular and Molecular Medicine, 2012, 16, 1421-1434.	3.6	13
34	New inhalation-optimized itraconazole nanoparticle-based dry powders for the treatment of invasive pulmonary aspergillosis. International Journal of Nanomedicine, 2012, 7, 5475.	6.7	51
35	Lactose characteristics and the generation of the aerosol. Advanced Drug Delivery Reviews, 2012, 64, 233-256.	13.7	168
36	Solid dispersions of itraconazole for inhalation with enhanced dissolution, solubility and dispersion properties. International Journal of Pharmaceutics, 2012, 428, 103-113.	5.2	55

NATHALIE WAUTHOZ

#	Article	IF	CITATIONS
37	Temozolomide-Based Dry Powder Formulations for Lung Tumor-Related Inhalation Treatment. Pharmaceutical Research, 2011, 28, 762-775.	3.5	37
38	In vivo assessment of temozolomide local delivery for lung cancer inhalation therapy. European Journal of Pharmaceutical Sciences, 2010, 39, 402-411.	4.0	36
39	Simple di- and trivanillates exhibit cytostatic properties toward cancer cells resistant to pro-apoptotic stimuli. Bioorganic and Medicinal Chemistry, 2010, 18, 3823-3833.	3.0	40
40	Lycorine, the Main Phenanthridine Amaryllidaceae Alkaloid, Exhibits Significant Antitumor Activity in Cancer Cells That Display Resistance to Proapoptotic Stimuli: An Investigation of Structureâ°'Activity Relationship and Mechanistic Insight. Journal of Medicinal Chemistry, 2009, 52, 6244-6256.	6.4	214